Ron Leuty is a Senior Reporter at SF Business Times. He specializes in biotech and healthcare, covering a range of topics including alternative medicine, manufacturing, and sports business, with a focus on California and the San Francisco area. Ron's work has been featured in Yahoo Finance, San Francisco Business Journal, NewsBreak, and Charlotte Business Journal.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
San Francisco, United States (Local)
Not enough data
This information evolves through artificial intelligence and human feedback. Improve this profile .
Startup ResVita Bio targets rare, deadly skin disease with a bacterial factory
By: Ron Leuty
Abrupt end of Pfizer's hemophilia A gene therapy deal with Sangamo is the latest in a line of flip-flops between the big drug maker and smaller Bay Area partners.
By: Ron Leuty
Post-bankruptcy, cancer-focused biotech company urges others to hire its employees: 'They rock'
By: Ron Leuty
This cancer-focused drug-development company is laying off 40% of its workforce to stretch out its cash.
By: Ron Leuty
Age is an issue of mind over matter — h/t Mark Twain — but early ALS clinical trial results from Google-backed aging-disease drug maker Calico do matter.
By: Ron Leuty
South San Francisco biotech Pionyr was sold two years ago. Now three of its leaders want to test a trio of drugs beyond cancer.
Why biotech startup Tenvie sees promise in drugs from founders' old company
By: Ron Leuty
In a bid to help the immune system of autoimmune disease patients reset, a San Francisco startup startup has raised $120 million.
California biotech lobbying group cuts staff ahead of leadership change
At biotech's biggest conference, UC Berkeley shows off startups
(833) 317-6278 
